sive diffuse large B-cell lymphoma and that amplification of oncogene REL (maps to chromosome 2p16) has been found in a high percentage of human B-cell lymphoma, 4 we attempted to determine whether the dmins in our patient contain the REL gene.
We searched the National Center for Biotechnology Information (NCBI) database and identified a bacteria-derived artificial chromosome (BAC) clone RP11-373L24 (BACPAC Resources, Oakland, CA, USA) that contains the REL gene. Isolated DNA from this clone was labeled with fluorochromes following the protocol described in our previous studies 5 and validated as a FISH probe on normal controls. This probe was then used to characterize dmins in our patient. Positive hybridization signals were observed on the dmins (Figure 1c ), demonstrating the presence of the REL gene in the dmins. In order to address whether the REL amplification was present in the initial lymph node biopsy, we performed retrospective FISH analysis with the same probe on paraffin-embedded tissue. No REL amplification was evident (Figure 1d ). In addition, we used Ki-67/MIB-1 immunoperoxidase stain 6 to compare the mitotic index in the initial lymph node biopsy and in the relapsed bone marrow. No significant changes were observed.
In this report, we demonstrated REL amplification in the form of dmins in a patient with follicular lymphoma. To our knowledge, this is the first report of direct demonstration of REL-positive dmins in lymphoma. Interestingly, no REL amplification was detected in the initial lymph node biopsy and the REL-positive dmins appeared to be the sole detectable secondary aberration at the time of relapse. REL encodes a nuclear factor-kB transcription factor. It is amplified or mutated in several cases of human B-cell lymphoma and can transform chicken lymphoid cells in vitro. REL regulates the expression of numerous cellular genes including genes involved in lymphoid cell development and proliferation. 4 REL may also cooperate with other genes in B-cell tumorigenesis. One of the cooperating candidates is BCL11A, which is located near REL and is frequently coamplified with REL in B-cell lymphomas. 7 Owing to the limited amount of available specimen, we were not able to determine the boundary of the dmin in our patient. However, we believe BCL11A is likely to be present in the dmins. This is because the estimated size of the dmin in this case is greater than 5000 kb and the distance between REL and BCL11A is about 300 kb. BCL11A encodes a zinc-finger Kruppel-like transcription repressor protein, but its target genes remain to be revealed.
Although REL gene amplification has been reported in 15-20% of large B-cell lymphoma and 15-20% of follicular B-cell lymphoma, 4 it is unclear if such amplifications play a key role in oncogenesis. Based on the finding that there was no clear correlation between REL amplification and its nuclear accumulation, Houldsworth et al. 8 suggested that REL amplification may not lead to abnormal REL activation. However, others have proposed that REL amplification may be important at an earlier growth stage. 4 In a recent study, In a small percentage of patients with acute leukemia, conversion of cell lineage can occur at relapse. 1 Such conversion of cell lineage usually concerns a switch from precursor-B-acute lymphoblastic leukemia (ALL) to acute myeloid leukemia (AML) and is most frequently assumed to represent a therapy-related secondary malignancy. 2 However, true lineage switches of clonally related leukemic cells have also been described. 3, 4 To establish a true lineage switch (i.e. the leukemic cells at diagnosis and at relapse are clonally related), molecular techniques such as analysis of immunoglobulin (Ig) and/or T-cell receptor (TCR) genes are required. The exact mechanism resulting in a true lineage switch are still not understood, but possible explanations include the preferential outgrowth of a minor AML subclone present at diagnosis, a true therapy-induced immunophenotypic shift or outgrowth of an undifferentiated pre-leukemic clone.
We present a 63-year-old man with no medical history, who was admitted to the hospital because of fatigue, coughing, shortness of breath and night sweats. He had no fever and his weight was stable. Physical examination showed a tachypnoeic man with a tachycardia. There was a damped percussion and no breathing sounds at the right side of the thorax. An enlarged lymphoma was palpable in the right axilla. Laboratory examination showed an elevated serum lactate dehydrogenase of 1100 U/l (normal range 0-449 U/l) and a leukocytosis of 23 Â 10 9 /l (normal range 3.5-10.0 Â 10 9 /l). The hemoglobin level was 8.8 mmol/l (normal range 8.6-10.5 mmol/l) and the platelet count was 195 Â 10 9 /l (normal range 150-370 Â 10 9 /l). The May-Grü nwald-Giemsa-stained blood smear revealed 19% blasts, 76% myeloid cells (mostly mature granulocytes) and 5% mature lymphocytes. The hypercellular bone marrow aspirate showed 78% small-to medium-sized blasts, some with an irregularly formed or cleaved nucleus. There was a fine chromatin structure and an occasional small nucleolus. No granulation was seen in the light-gray-stained cytoplasm. Eosinophilia was not observed. By cytochemistry, the blasts were negative for the myeloperoxidase staining. Immunophenotypic analysis showed that the blasts present in the peripheral blood and bone marrow had a low to medium size and the immunophe- Figure 1c ). Based on morphology and immunophenotyping, the diagnosis precursor T-cell acute lymphoblastic leukemia (T-ALL) was made according to the WHO criteria. Cytogenetic analysis of the lymphoblasts in bone marrow, using standard banding techniques and classification according to the International System for Human Cytogenetic Nomenclature ISCN 2005, revealed an aberrant karyotype: 46-47,XY,add(4)(q2?),À5, þ 13, À15,add(16)(p1?2), þ r, þ mar[cp12]/46,XY [9] . Fluorescence in situ hybridization was performed using the TLX3 translocation probe set (DAKO Cytomation, Glostrup, Denmark) and the BCR-ABL ES probe set (Vysis, Abbott Laboratories, North Chicago, USA) to identify any known cryptic T-ALL-associated chromosomal abnormalities. No TLX3 translocation, BCR-ABL translocation or ABL amplification could be detected.
A chest radiograph revealed a pleural effusion in the right hemithorax. The pleural fluid showed small-to medium-sized blasts (Figure 1a ). These cells were immunophenotypically similar to the malignant blasts in the bone marrow, indicative of a pleural localization of the T-ALL. The myeloperoxidase staining was negative. Computed tomography (CT) scanning of the neck, chest and abdomen showed a pathologic lymphoma in the right axilla, a pathologic mass in the cardiomediastinum with in-growth of the pericardium and encasement of the truncus pulmonalis, the left pulmonary vein and the left atrium and the right hilus with complete collapse of right lung, massive pleural effusion of the right hemithorax and retroperitoneal lymphadenopathy. Repeated morphologic and immunophenotypic analysis of the liquor cerebrospinalis did not show any evidence of leptomeningeal T-ALL localization.
Immediately after diagnosis, the patient was treated with chemotherapy including a pre-induction course containing cytarabine, etoposide and methotrexate, followed 3 weeks after diagnosis by an ODA remission induction course (vincristine, adriamycin, dexamethasone). After hematological recovery (7 weeks after diagnosis), a second ODA course was administered. In addition to the systemic chemotherapy, the patient was treated five times with prophylactic intrathecal chemotherapy (methotrexate and dexamethasone). Four weeks after the start of the first ODA course and 3 weeks after the start of the second ODA remission induction course, the effect of the treatment was evaluated using blood and bone marrow examination and CT scan imaging. Both evaluation moments showed a complete morphologic response in blood and bone marrow. However, immunophenotypic analysis of the bone marrow revealed residual disease with 0.5% of the leukocytes with the aberrant T-ALL phenotype identical to diagnosis. CT scan imaging showed more than 50% reduction of the lymphadenopathy and decrease of pleural effusion. Thirteen weeks after diagnosis, the treatment was continued by a consolidation course with cytarabine and asparaginase. Blood, bone marrow and CT scan evaluation 3 weeks after the start of the consolidation course showed a morphologic, immunophenotypic and cytogenetic complete response. CT scan examination showed a further reduction of the lymphadenopathy, but an increase of the pleural effusion. Because of this discrepancy, the pleural fluid was analyzed. Large blast cells were seen in the MayGrü nwald-Giemsa staining (Figure 1b) . The lobated nucleus showed a fine chromatin structure and one or two prominent nucleoli. The blue, abundant cytoplasm showed small vacuoles and dark granules were seen over the nucleus and cytoplasm. The large cells were positive for the myeloperoxidase staining and it was concluded that the pleural fluid contained an infiltrate of immature myeloid cells with an atypical morphology. Immunophenotypic analysis showed an abnormal cell population with the immunophenotype CD45 [2] ,À17,À18 [5] ,À21, þ r, þ mar [3] [cp16], indicative of clonal evolution when compared to the karyotype at diagnosis. Analysis of diagnosis and relapse samples did not show the presence of internal tandem duplications or activating mutations (exon 20) in the FLT3 gene.
5 MLL-AF4, MLL-AF9 and MLL-ENL fusion transcripts could not be detected. 6 To establish a potential clonal relationship between the cells at diagnosis and at relapse, DNA was isolated from bone marrow at diagnosis and pleural fluid at relapse for analysis of Ig/ TCR gene rearrangements. At diagnosis, four TCR gene rearrangements were identified in the T-ALL: a bi-allelic VgIV-Jg1.3/2.3, one Vd2-Jd1 and one Dd2-Dd3 rearrangement. Mixed heteroduplex analysis 3 showed that all four rearrangements were preserved in the myeloid cells present in the pleural fluid at relapse (Figure 1e ), thereby confirming a clonal relationship between both immunophenotypically different cell populations.
From the results of the pleural fluid, the diagnosis of refractory disease was made. Subsequently, an additional bone marrow aspirate was performed and no abnormal cells were found by cytological and flow cytometric analysis. However, in one slide of this bone marrow aspirate, a small amount of the same large vacuoled cells was seen. Because of the poor clinical condition of the patient and serious liver enzyme elevations owing to medication, no further salvage treatment could be given. The patient died because of progressive disease 6 months after diagnosis.
The here presented case is remarkable, as true lineage switches from T-ALL to AML are extremely rare 7 and as both the original T-ALL as well as the myeloid relapse were located extramedullary (in the pleural fluid, next to the bone marrow at diagnosis). By morphology and immunophenotyping, the cells at relapse appeared to be of myeloid origin, but further characterization (assignment of lineage and maturation stage) appeared to be difficult. Based on the presence of identical Ig/TCR gene rearrangements and partly comparable cytogenetic abnormalities at diagnosis and relapse, the T-ALL population at diagnosis and the myeloid population at relapse were, however, clearly clonally related. As the abnormal myeloid cell population could not be detected at primary diagnosis, outgrowth of a minor myeloid subclone seems unlikely. We therefore hypothesize that an undifferentiated pre-leukemic clone with both T-cell and myeloid potential was present at diagnosis and, under pressure of the T-ALL-directed therapy, grew out as a myeloid cell at relapse. In line with this, recent studies have indicated that cells with both T-cell as well as myeloid potential may exist. Chronic myelogenous leukemia (CML) is characterized by the presence of a BCR-ABL fusion gene, which is the result of a reciprocal translocation between chromosomes 9 and 22. The BCR-ABL gene product exhibits constitutive tyrosine kinase activity, which plays a critical role in BCR-ABL-induced transformation. Imatinib mesylate represents a potent inhibitor of BCR-ABL tyrosine kinase activity and demonstrated high efficacy in inducing cytogenetic remissions in CML patients. 1 Recent in vitro studies have investigated the impact of imatinib on phenotype and function of human dendritic cells (DCs), which play an important role for the induction of innate and adaptive antitumor immunity. Thus, it has been shown that CML-derived DCs display an improved ability of antigen presentation in the presence of imatinib. 2 Further data revealed that imatinib does neither inhibit the immunophenotypic profile and migration of CML-derived DCs nor their ability to stimulate T-cell proliferation (below 2.5 mM imatinib). 3 More recently, it has been reported that exposure to imatinib only minimally affects the differentiation of bcr-abl þ and normal monocytes into DCs and does not impair the DC-mediated polarization of naive CD4 þ T cells. 4 In contrast, Appel et al. 5, 6 demonstrated that imatinib efficiently inhibits the differentiation of CD34 þ hematopoietic progenitors and monocytes into DCs and their ability to induce cytotoxic T-cell responses. Whereas all these reports are based on DCs that are generated after several days in the presence of various cytokines studies investigating the impact of imatinib on native human blood DCs are very limited.
SlanDCs (formerly termed M-DC8 þ DCs) are a major subset of inflammatory myeloid human blood DCs, which mainly differ from other blood DC subpopulations by the selective expression of 6-sulfo LacNAc, representing a carbohydrate modification of P-selectin glycoprotein ligand-1. 7 Recently, we documented that the majority of slanDCs display a spontaneous maturation after 6 h in the absence of exogeneous cytokines and that these cells represent principal producers of the immunomodulatory cytokine interleukin (IL)-12 and the cytotoxic effector molecule tumor necrosis factor (TNF)-a. 7, 8 Additional data revealed that slanDCs efficiently induce neoantigen-specific CD4 þ T cells, activate tumor-reactive CD8 þ cytotoxic T cells and improve the tumoricidal potential of natural killer (NK) cells. In the present study, we investigated the effect of imatinib on maturation and cytokine production of slanDCs. In addition, we evaluated its impact on the capacity of slanDCs to promote proliferation and differentiation of CD4 þ T-helper cells and to increase the tumoricidal potential of NK cells. Blood samples were obtained from healthy donors and imatinib-treated CML patients in complete cytogenetic remission with informed consent. Immunomagnetic isolation of slanDCs at high purity (490%) was performed as described. 7 To determine the impact of imatinib on maturation and cytokine expression of slanDCs, freshly isolated DCs were cultivated in the presence of 5 mM imatinib dissolved in dimethyl sulfoxide (DMSO) or equal amounts of DMSO as a control. SlanDCs from CML patients in complete cytogenetic remission under imatinib treatment were cultured without imatinib. After 6 h, expression levels of human leukocyte antigen (HLA)-DR, CD83 and CD86 were determined by fluorescence-activated cell sorting (FACS) analysis, which was performed as described. 7 Imatinib did not influence the surface expression of HLA-DR, CD83 and CD86 on slanDCs from healthy donors (Figure 1a-i) or CML patients (data not shown). To investigate cytokine production, slanDCs were maintained for 6 h to allow spontaneous maturation, washed and subsequently stimulated with 1 mg/ml lipopolysaccharide (LPS) for additional 18 h. FACS analysis or enzymelinked immunosorbent assay revealed that the capacity of LPSactivated slanDCs from healthy donors or CML patients to produce TNF-a and IL-12 was not impaired by imatinib (Figure  1j-n) . The latter observation is in agreement with a previous report, indicating that plasmacytoid DCs from CML patients responding to imatinib can secrete significant amounts of interferon (IFN)-a, compared to healthy donors. 9 To investigate the influence of imatinib on slanDC-mediated proliferation and programming of CD4 þ T cells, DCs from healthy donors were maintained for 6 h in the presence of imatinib and washed. To determine T-cell proliferation, slanDCs were cocultured with immunomagnetically isolated allogeneic CD4 þ T-helper cells in the presence of LPS for 4 days. 3 H-thymidine (1 mCi) was added to each well for the last 18 h of
